Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Caleb, Bliss"'
Publikováno v:
BMC Pharmacology and Toxicology, Vol 19, Iss 1, Pp 1-13 (2018)
Abstract Background Accumulation of toxic free cholesterol in hepatocytes may cause hepatic inflammation and fibrosis. Volixibat inhibits bile acid reuptake via the apical sodium bile acid transporter located on the luminal surface of the ileum. The
Externí odkaz:
https://doaj.org/article/51b92e3e1e784f6189db7c27916dcfc3
Autor:
Tomáš Vaňásek, Miles P. Sparrow, Maria Kłopocka, Paul Hellstern, Kenneth J. Gorelick, Martina Goetsch, Xavier Hébuterne, Fabio Cataldi, Caleb Bliss, Dino Tarabar, Charu Gupta, William J. Sandborn, Miloš Greguš, Michael Hoy, Severine Vermeire, Silvio Danese, Joo Sung Kim, Walter Reinisch
Publikováno v:
Journal of Crohn's & Colitis
Background and Aims Ontamalimab, a fully-human monoclonal antibody targeting MAdCAM-1, induced remission in patients with moderate-to-severe ulcerative colitis [UC] in the TURANDOT study. We aimed to assess long-term safety, tolerability, and efficac
Autor:
Michael Huss, Sepehr Farahbakhshian, Brigitte Robertson, Caleb Bliss, Tamara Werner-Kiechle, David R Coghill
Publikováno v:
European Child & Adolescent Psychiatry
Several recent phase 3 clinical trials of attention-deficit/hyperactivity disorder (ADHD) medications have used the Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P). Here, we assess WFIRS-P response in individual patients in two pivot
Autor:
Michael Huss, Jeffrey H. Newcorn, Bryan Dirks, Keith McBurnett, Amaia Hervás, Caleb Bliss, Andrew J. Cutler, Joseph Gao
Publikováno v:
European Neuropsychopharmacology. 29:432-443
The present study investigated whether symptom reduction in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with guanfacine extended release (GXR) can be explained by sedative effects of the medication. Data from
Publikováno v:
Neuropsychiatric Disease and Treatment
Leslie Citrome,1 Judith C Kando,2 Caleb Bliss3 1Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY, USA; 2Shire, Global Medical Affairs, Lexington, MA, USA; 3Shire, Biostatistics, Lexington, MA, USA Objectives: I
Publikováno v:
CNS Drugs
Background SPD489-404 was the first 2-year safety study of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. In accordance with advice from the European Medicines Agency, assessment
Publikováno v:
Journal of Attention Disorders
Objective: To assess relationships between treatment-associated changes in measures of ADHD symptoms, functional impairments, and health-related quality of life in children and adolescents with ADHD. Method: Pearson correlation coefficients were calc
Autor:
Melissa Palmer, Lee Jennings, Caleb Bliss, Nicholas Siebers, Debra G. Silberg, Patrick Martin
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 43:91-101
Volixibat is a potent inhibitor of the apical sodium-dependent bile acid transporter in development for the treatment of nonalcoholic steatohepatitis. This phase 1, open-label study investigated the absorption, distribution, metabolism, and excretion
Autor:
Silvio Danese, Severine Vermeire, Paul Hellstern, Fabio Cataldi, Caleb Bliss, Tomáš Vaňásek, Martina Goetsch, Michael Hoy, Xavier Hébuterne, Kim Joo Sung, Miloš Greguš, Kenneth J. Gorelick, Charu Gupta, William J. Sandborn, Dino Tarabar, Walter Reinisch, Miles P. Sparrow, Maria Kłopocka
Publikováno v:
American Journal of Gastroenterology. 114:S21-S22
Autor:
Miles P. Sparrow, Walter Reinisch, Maria Kłopocka, Joo Sung Kim, Paul Hellstern, Kenneth J. Gorelick, Charu Gupta, William J. Sandborn, Martina Goetsch, Dino Tarabar, Silvio Danese, Fabio Cataldi, Caleb Bliss, Xavier Hébuterne, Severine Vermeire, Miloš Greguš, Tomáš Vaňásek
Publikováno v:
American Journal of Gastroenterology. 114:S448-S449